retatrutide phase 2 trial results Results: 28.3% Weight Loss Data Retatrutide: A Triple Agonist Shaping
Description
: ,
Cell Host Microbe 32:209-226.e7
No offboarding plan Programs without a tapering strategy leave members on medication indefinitely which drives up long-term spend
Cookies de anlisis Utilizamos cookies de Google Analytics para cuantificar el nmero de usuarios que visitan la Web
2019Oct;71(4):793801
Study type: off-treatment extension of a randomized trial
